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ABBREVIATIONS 
 
NASH  - Non Alcoholic Steato Hepatitis 
NAFLD - Non Alcoholic Fatty Liver Disease 
T2DM - Type 2 Diabetes Mellitus 
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HCV - Hepatitis ‘C’ Virus 
TGL - Triglyceride 
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INTRODUCTION 
 
Non alcoholic fatty liver disease (NAFLD) is one the most common 
liver disorders worldwide. “It is defined as liver fat exceeding 5-10% by weight 
and exists as a spectrum from steatosis (which is usually stable) to 
steatohepatitis or non alcoholic steatohepatitis (NASH) (cellular ballooning, 
necroapoptosis, inflammation and fibrosis) which progress to cirrhosis in 15 – 
20% ” (1). In the United States NAFLD stands as fourth cause of liver 
transplantation. Non alcoholic fatty liver disease is closely associated with 
obesity, insulin resistance and dyslipidemia. The prevalence of NASH is 
increasing in line with increasing incidence of sedentary life style, obesity and 
diabetes mellitus. Previously many patients were thought to have cryptogenic 
cirrhosis show clinical features of NAFLD suggesting that the cause of that 
cirrhosis could be unrecognized NAFLD. 10-75% of NAFLD patients have 
T2DM and 21-72% of diabetic patients are found to have NAFLD .[2]  NAFLD 
and diabetes mellitus are highly dependent on genetic background and dietary 
factors.(3)  The term NASH or Non alcoholic steatohepatitis was introduced by 
Ludwig et al., describing the lesion in various degree of severity in patients 
without significant ethanol exposure .(3)   
Insulin resistance is very common in NAFLD (4,5,6) It can be 
demonstrated in major insulin targets including adipose tissue (persistent 
lipolysis), muscle (diminished glucose disposal) and liver (failure to suppress 
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glucose release). It is estimated that up to 75% of type 2 diabetic have fatty 
infiltration. (7) 
Liver biopsy remains the standard test for confirming the diagnosis, 
staging fibrosis, grading activity and judging response to treatment. But it has 
many limitations like patient inconvenience, cost, difficulty in performing in 
obese patients, sampling error, procedure related complication and even 
mortality. Liver enzymes and various imaging modalities can be used in the 
diagnosis of NAFLD. But these will not exactly assess steato hepatitis and 
fibrosis. These patients are investigated by non invasive modality called 
fibroscan (Transient elastography ). This has become a popular non invasive 
device to assess the liver hardness or stiffness and quantification of liver 
steatosis with the Controlled Attenuation Parameter (CAP). Since fibrous tissue 
is harder than normal liver, the degree of hepatic fibrosis can be inferred from 
liver the hardness. The results are expressed in kilopascals (Kpa). 
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AIM OF THE STUDY 
 
To assess the utility of transient elastography (fibroscan) as a screening 
tool to detect the presence of fibrosis of liver in the patients with diabetes 
mellitus with non alcoholic fatty liver disease. 
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REVIEW OF LITERATURE 
 
HISTORIC PERSPECTIVE: 
              Ludwig et alin, a Mayo Clinic pathologist, coined the term NASH in 
non-alcoholics in a paper published in 1980.(3) 
              In 1952 Zelman described liver biopsy findings in 19 obese men that 
included steatosis and varying degrees of inflammation and fibrosis. (8) 
 Various researches to describe the etiopathogenesis, natural history is 
stated below; 
1. 1950 - cirrhosis noted in diabetes 
2. 1970 -  jejuno-ileal bypass liver disease resembles alcoholic hepatitis 
3. 1979/80- Ludwig et al coined the term NASH for steatohepatitis in 
non-alcoholics 
4. 1994 – expanded scope of NASH (Bacon et al) 
5. 1996 – CYP2E1 induced in rodent dietary model Endotoxin induces 
inflammation in steatotic liver 
6. 1998 – CYP2E1 induced in human NASH; Pivotal importance of 
insulin resistance 
7. 1999 – Several animal models;    First clinical trial 
8. 2002 - ~60 papers/year 
 AASLD single topic conference 
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 First European and Japanese single topic conferences 
 NASH established as part of insulin resistance syndrome 
9. 004 – Release of first book on NAFLD/NASH 
 
 
INCIDENCE AND PREVALENCE: 
            In general population, 10-24% NAFLD was detected in various 
countries. The estimation increases from 57.5% (9) to 74% (10,11) 
 Many meta analysis was done to describe the burden of NAFLD. One 
meta analysis done in febraury 2016 named “Global epidemiology of non 
alcoholic fatty liver disease- meta analytic assessment of prevalence, incidence 
and outcomes.” According to this study, average prevalence of NAFLD in the 
adult population was 25.24%. The stratification by region as follows: 
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REGION N PREVALENCE(%) 
Africa 2 13.48 
Asia 14 27.37 
Europe 11 23.71 
Middle East 3 31.79 
North america 13 24.13 
South America 2 30.45 
overall 45 25.24 
 
Another study conducted by Lonardo A, Bellantoni S, et al in 2015 showed the 
following results. 
Prevalence of NAFLD by various studies (14) 
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Prevalence of obesity and NAFLD as follows: 
 
INDIAN SCENARIO:  
 There are only limited study on prevalence of NAFLD in India. 
(12)Chitturi et al in his study described prevalence of fatty liver as 15.8% and 
24% in Western India and Eastern India respectively. (13)Mohan et al studied 
prevalence of NAFLD in type 2 diabetics and found it to be 54.5%. Overall 
incidence of insulin resistance is high in Asian populations. 
LIVER DISEASE IN DIABETES MELLITUS: 
2. Liver disease occurring as a consequence of diabetes mellitus. 
- glycogen deposition 
- steatosis and non alcoholic steatohepatitis (NASH) 
- Fibrosis and cirrhosis 
- Biliary disease, cholelithiasis, cholecystitis 
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- Complications of therapy of diabetes (cholestatic and 
necroinflamamatory) 
2. Abnormalities of glucose homeostasis occurring as a complication of liver 
disease can be present in 
- Hepatitis 
- Cirrhosis 
- Hepatocellular carcinoma 
- Fulminant hepatic failure 
3. Liver disease occurring coincidentally with diabetes and abnormalities of 
glucose homeostasis. 
- hemochromatosis 
- Glycogen storage disease 
- Autoimmune biliary disease 
Fatty liver is well recognized complication of type 2 diabetes when 
compared type 1 diabetes. Type 2 diabetes have 70% correlation to NAFLD 
regardless of blood glucose control. 
 Increasing evidence indicates that NAFLD increases the risk of 
cardiovascular complications, micro and macrovascular complications. The 
micro and macrovasuclar disease have a great impact on economy of the 
patient. Both NAFLD and diabetes mellitus increases the risk of developing 
hepatocellular carcinoma. 
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 Familial clustering of NASH and NAFLD could represent inherited 
genetic predisposition or common environmental factors such as dietary habits 
and activity levels.(14,15,16) The finding of impaired skeletal muscle 
mitochondrial metabolism and insulin resistance in the offspring of patients 
with diabetes mellitus suggest a genetic risk related to intracellular fat 
metabolism.(17) 
NAFLD CAUSES ARE AS FOLLOWS: (18) 
PRIMARY:   
1. Obesity 
2. Glucose intolerance 
3. Type 2 diabetes mellitus 
4. Hypertriglyceridemia 
5. Low HDL 
6. Cholesterol 
7. Hypertension 
NUTRITIONAL: 
1. Protein-calorie malnutrition 
2. Rapid weight loss 
3. Gastrointestinal bypass surgery 
4. Total parenteral nutrition 
5. Vitamin B12 deficiency 
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DRUGS: 
1. Glucocorticoids 
2. Estrogens 
3. Tamoxifen 
4. Amiodarone 
5. Methotrexate 
6. Diltiazem 
7. Zidovudine 
8. Sodium Valproate 
9. Aspirin 
10. Tetracycline 
11. Cocaine 
METABOLIC: 
1. Lipodystrophy 
2. Hypopituitarism 
3. Dysbetalipoproteinemia 
4. Weber-Christian disease 
5. Wilsons disease 
6. Anderson’s disease 
7. Mauriac syndrome 
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TOXINS: 
1. Amanita phalloides mushroom 
2. Phosphorus poisoning 
3. Petrochemicals 
4. Bacillus cereus toxin 
5. Carbon tetrachloride 
6. Vinyl chloride 
7. Ethyl bromide 
INFECTIONS: 
1. Human Immunodeficiency virus 
2. Hepatitis C 
3. Small bowel diverticulosis with bacterial overgrowth. 
PATHOGENESIS OF NAFLD: 
 Lipid accumulation in the liver results from imbalance between overall 
calorie intake and utilization which is the characteristic of metabolic syndrome. 
Hepatic fat results from several possible mechanisms like synthesis of new 
fatty acids mainly from carbohydrate precursors (de novo lipogenesis), uptake 
of circulating fatty acids (non esterified fatty acids -NEFA) derived from 
adipose tissue lipolysis, uptake of diet derived chylomicron remnants, uptake of 
VLDL derived LDL remnants. Liver fat is disposed of by either oxidation or 
lipoprotein secretion espectially as VLDL. NAFLD appears to be driven 
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especially by NEFA uptake , de novo lipogenesis and altered lipid export. 
Excess Free Fatty Acids (FFA) appears to promote permeabilization of 
lysosomes and mitochondria with release of cathepsins and cytochrome C, 
including caspases which activate apoptosis pathway. 
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Mechanism of Hepatocellular injury in NASH can be encapsulated in 
the “two hit hypothesis” – accumulation fat followed by oxidative injury.(19). .  
Additionally, a further component called third hit has been added to 
explain inadequate hepatocyte proliferation. Impaired capacity to regenerate 
leads to cell death with impaired regeneration of hepatocyte progenitors 
represent the third hit. 
CAUSES OF TRIGLYCERIDES ACCUMULATION IN LIVER: 
INCREASED FATTY ACID INFLUX: 
1. Obesity  
2. Insulin resistance 
3. Diet 
INCREASED FATTY ACID SYNTHESIS: 
1. Hyperinsulinemia 
2. Excess carbohydrate food intake 
3. Leptin deficiency 
INCREASED FATTY ACID OXIDATION 
1. Hyperinsulinemia 
2. genetic disorders 
3. Leptin deficiency 
4. Drugs 
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DECREASED VLDL ASSEMBLY: 
1. Genetic disorder 
2. Insulin resistance 
3. Drugs 
 
The process of fibrosis which occurs after the formation of fatty liver involves 
series of mechanism.  
1. Activation of liver kupffer cells  
2. Peroxidation of lipids in the mitochondria  
3. Oxidative damage to the mitochondria  
4. Altered function in the mitochondria  
5. Alteration in the cytokine levels 
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FIBROGENESIS IN NON ALCOHOLIC STEATOHEPATITIS: 
Final death may results from combination of necrosis and apoptosis 
(necroapoptosis).(20) The activation of caspase 3 leads to fragmentation of 
cytokeratin 18. This leads to the formation of Mallory denk bodies.(21) 
Accumulation of free fatty acids and impaired function of Endoplasmic 
reticulum activated Apo B100 leads to accumulation of misfolded proteins  
within the endoplasmic reticulum.(22) Pro inflammatory cytokines are activated, 
accumulation of inflammatory infiltrates and activation of collagen producing 
hepatic stellate cells characterized by transition from a vitamin A rich quiescent 
cell to a proliferating fibroblast.(23) 
 Progression of fibrosis may also depend on an altered repair process 
with impaired hepatocyte replication and increased activity of hepatic 
progenitor cells leading to a ductular reaction in the portal tracts. 
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Many systemic factors are also involved in the development of the 
above process including insulin/glucagon level, the adipose organ, adrenergic 
system and thyroid axis. 
Hepatic and extrahepatic insulin resistance is present in the majority of 
patients and contributes to the major cause for the pathogenesis of the disease. 
The following image shows the mechanism of fibrogenesis. 
 
The molecular pathogenesis of insulin resistance seems to be multifactorial, 
and several molecular targets involved in the inhibition of insulin action have 
been identified. Insulin resistance leads to fat accumulation in hepatocytes by 
two main mechanisms; lipolysis and hyperinsulinemia. 
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Liver injury worsens with the presence of diabetes in the patients with  NAFLD 
and doubles the prevalence of cirrhosis from 10% to 25%. 
   
NATURAL HISTORY AND PROGNOSIS: 
Various factors like obesity, sedentary life styles, genetic factors will 
lead to insulin resistance. This in turn leads to type 2 diabetes, hypertension 
and hyperlipidemia. All these factors leads to the formation of NASH or simple 
steatosis. NASH with severe fibrosis are one of the worst prognosis. (24) 
 In some cases the fibrosis remain static for years, in some it improves, in 
some patients it gradually worsens and finally leads to cirrhosis and 
hepatocellular carcinoma. 
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Many studies showed the prognosis of NASH and the few such studies 
are listed below.(25) 
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CLASSIFICATION OF NAFLD:(26)       
CATEGORY PATHOLOGY 
CLINICOPATHOLOGICAL 
CORRECTION 
TYPE 1 Simple steatosis 
Known to be non-
progressive 
TYPE 2 
Steatosis plus lobular 
inflammation 
Probably benign (not 
regarded as NASH) 
TYPE 3 
Steatosis, lobular 
inflammationand ballooning 
degeneration 
NASH without fibrosis-may 
progress to cirrhosis 
TYPE 4 
Steatosis, ballooning 
degeneration and Mallory 
bodies, and/or fibrosis 
NASH with fibrosis-may 
progress to cirrhosis and 
liver failure 
 
NAFLD OUTCOMES: 
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FACTORS INVOLVED IN PATHOGENESIS: 
 
 
CLINICAL FEATURES :            
Most of the patients with NAFLD are usually asymptomatic(27). Some 
complaints of discomfort in the right hypochondrium (28 ) The majority of 
patients are overweight with BMI of  >25 kg/m2, and one-third have metabolic 
syndrome.(29,30,31 ) Hepatomegaly present in some cases but signs of chronic 
liver disease is uncommon. 
Hepatomegaly is the only physical finding in most patients. Acanthosis 
nigricans may be seen in children with nonalcoholic fatty liver disease.(32) 
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Findings of chronic liver disease and diminished number of platelets suggest 
that advanced disease with cirrhosis is present. A high proportion of patients 
with cryptogenic cirrhosis share many of the clinical and demographic features 
of patients with nonalcoholic fatty liver disease, (33) suggesting that their 
cryptogenic cirrhosis is unrecognized nonalcoholic fatty liver disease.  
Common symptoms and signs of 400 subjects with NAFLD (Data from 
the NAFLD clinic at Virginia Commonwealth University, previously 
unpublished data).(38) 
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The above table shows that majority are asymptomatic and most of the patients 
are obese. 
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TREATMENT OF NAFLD: 
 
 
 
1. Treatment of associated disorders like gradual weight loss, control 
diabetes mellitus, control dyslipidemia. 
2. Pharmacological approach to treat insulin resistance, dyslipidemia, 
giving anti oxidants. 
3. Liver transplantation is the definitive treatment in case of severe fibrosis 
or cirrhosis. 
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LABORATORY ABNORMALITIES: 
In patients with NAFLD, aspartate aminotransferases and alanine 
aminotransferases are mild to moderately elevated. This is most common and 
sometimes only laboratory abnormality found. The ratio of aspartate 
aminotransferase to alanine aminotransferase is usually less than 1, but may 
increases as fibrosis advances, and so accuracy in diagnosing patients with 
cirrhotic nonalcoholic fatty liver disease becomes less.(34) Serum alkaline 
phosphatase, gamma glutamyltransferase, or both are above the normal range 
in many patients, rise is not much when compared to alcoholic hepatitis. An 
ALT or AST value >300 IU/L should raise the suspicion of alternate cause.(35) 
The degree of abnormality is usually moderate and does not exceed 2-3 times 
the upper limit of normal values. But none of these tests are sensitive or 
specific enough to establish a diagnosis of NAFLD with great accuracy. 
Isolated elevation of SAP can also be seen.(36) 
Other abnormalities including hypoalbuminemia, a prolonged prolonged 
prothrombin time, and hyperbilirubinemias, may be found in patients with 
cirrhotic stage nonalcoholic fatty liver disease. 
CALCULATION OF INSULIN RESISTANCE: 
1. HOMA (homeostasis model assessment) >1.8 – 2 
2. QUICKI (quantitative insulin sensitivity check index) <0.35 
3. Rough estimate- Fasting insulin x fasting glucose- >700 
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LIVER IMAGING: 
Imaging of liver plays an important role in the clinical diagnosis of 
NAFLD and also for epidemiological purposes. But the conventional 
techniques are not accurate in grading the NASH and are insensitive to hepatic 
fat that is less than 20% by weight.(37)  Cross-sectional imaging is used to assess 
fat distribution (visceral versus peripheral fat) by determining the fat area at 
specific levels such as L4-5.(38) . 
USG abdomen is used as a first line imaging modality in patients 
suspected of liver disorders. It shows good correlation with the histological 
finding of fatty liver. In USG, the evidence of steatosis is seen as increased 
echogenicity (bright scan) . 
 
ABOVE FIGURE SHOWS USG GRADING OF STEATOSIS: 
A :NORMAL 
B: Grade 1(mild) – Increased hepatic echogenicity with visible periportal and 
diaphragmatic echogenicity. 
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C:Grade 2(moderate) - Increased hepatic echogenicity with imperceptible 
periportal echogenicity, without obscuration of diaphragm. 
 D:Grade 3(severe) -  Increased hepatic echogenicity with imperceptible 
periportal echogenicity, with obscuration of diaphragm. 
Doppler perfusion index is defined as the ratio of arterial blood flow to 
total blood flow in liver. Liver hemodynamics are altered in case of NAFLD.(39)  
Unenhanced computed tomography (CT) relies on attenuation 
differences  between the liver and spleen.(40) Sensitivity and specificity for fatty 
liver were 84%  and 99% respectively, for a spleen minus liver value of > 10 
Hounsfield units in one study.(41) 
 
Magnetic resonance proton spectroscopy is the most accurate means of 
quantifying steatosis.  
Chemical shift gradient – echo imaging with in phase and opposed- 
phase acquitions are used in MRI. MRI on T1 weighted images shows 
intracellular fatty infilteration and loss of signal on opposed phase chemical 
shift image. MR spectroscopy is capable of measuring accurately  adenosine 
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triphosphate (ATP), lipid peroxidation, and the phospholipid content of 
liver.(42) 
LIVER BIOPSY: 
Liver biopsy is the only way to confirm the presence or absence of 
NASH in a person with features of NAFLD, and histology remains the only 
criterion for fibrotic severity.(43)  The presence of warning signs of cirrhosis is a 
stronger indication for liver biopsy in order to document with higher certainity 
the cause of liver disease- occasionally , an unsuspected alternative cause of 
liver disease may be present.(43)   
LIVER BIOPSY – HISTOLOGY 
 
FIGURE A: Macro vesicular steatosis with inflammatory infilterate, hepatocyte 
ballooning and Mallory’s hyaline. 
FIGURE B: perivenular, pericellular and perisinusoidal fibrosis shown by 
Masson’s trichrome stainings in zone 3 (“CHICKEN WIRE” fibrosis). 
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GRADING OF STEATOSIS: (44) 
 
GRADING OF NECROINFLAMMATION: (AFTER BRUNT) (44) 
Grade Ballooning Lobular inflammation 
Portal 
inflammation 
GRADE 1 
MILD 
Occasional, zone 3 
hepatocytes 
Polymorphs and 
mononuclear cells, mild and 
scattered 
None or mild 
GRADE 2 
MODERATE 
Obvious, present in 
zone 3 
Polymorphs associated with 
ballooned hepatocytes+/- 
mild mononuclear cells 
None, mild or 
moderate 
GRADE 3 
SEVERE 
Marked, 
predominantly zone 3 
Polymorphs concentrated in 
areas of ballooning; 
inflammation more than in 
grade 2 
Mild or 
morderate, not 
marked. 
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STAGING OF FIBROSIS: 
 
NON INVASIVE ASSESSMENT OF NASH AND ADVANCED 
FIBROSIS: 
1. The NAFLD Fibrosis score 
2. Enhanced Liver Fibrosis Panel 
3. Transient elastography 
4. Circulating levels of cytokeratin 18. 
PREDICTORS OF MORE SEVERE HISTOLOGY IN NASH: 
1. age  >40-50 yeays 
2. degree of obesity 
3. hypertension 
4. overt diabetes mellitus 
5. hypertriglyceridemia 
6. elevated ALT 
7. elevated AST 
8. AST:ALT ratio >1 
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9. elevated serum IgA level 
10. family history of NASH or cryptogenic cirrhosis 
LIVER STIFFNESS (LS) MEASUREMENT: 
Liver stiffness named as modulus of elasticity which is based on the 
principle of Hooks law which is expressed as kilopascals (Kpa). LS is based on 
following characteristics: 
1. extracellular matrix, 
2. constraints or pressure applied, 
3. internal pressure inside the liver, 
4. viscous effects. 
TRANSIENT ELASTOGRAPHY: 
It is a non invasive ultrasound technique used to assess the fibrosis of 
liver. This has become a popular non invasive device to assess the liver 
hardness or stiffness and quantification of liver steatosis with the Controlled 
Attenuation Parameter (CAP). This fibroscans use “Vibration Controlled 
Transient Elastography” (VCTE) technology to generate precise quantitative 
measurements of key liver parameters. Liver hardness is evaluated by 
measuring the velocity of a vibration wave ( also called as shear wave ) 
generated on the skin. Shear wave velocity is determined by measuring the 
time taken by the vibration wave to travel to a particular depth inside the liver. 
Since fibrous tissue is harder than normal liver, the degree of hepatic fibrosis 
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can be inferred from liver the hardness. The results are expressed in kilopascals 
( kPa ). 
 The test is performed with the patient lying supine, an ultrasound-like 
probe is placed on the skin over the liver area, typically in the right mid-
axillary line. The patient will feel a ‘flick’ each time a vibration wave is 
generated by the probe. Approximately it takes around 10 minutes to perform 
this test. 
Fibroscan is especially used to assess the degree of liver scarring i.e., 
stage of liver disease. This is useful in patients with chronic liver disease, 
including chronic hepatitis C, chronic hepatitis B, alcoholic liver disease, fatty 
liver. This measurement is used to  
- Estimate the existing degree of liver damage. 
- Monitor disease progression or regression by serial measurements. 
- Guide prognosis and further management. 
Since this transient elastography doesnot measure he fibrosis directly 
some amount of over estimation i.e., false positive results may occur. It may 
occur in case of 
- Acute hepatitis 
- Cholestasis 
- Hepatocellular carcinoma 
- Congestion of liver 
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Unreliable readings are more frequently seen in the following patients. 
- Obesity (BMI > 30-35 kg/m2 ) 
- Older age 
- Presence of ascites 
- Metabolic syndrome ( increased waist circumference ) 
Conventional ultrasound is used to assess the structural integrity of liver 
but fibroscan is superior to ultrasound in detecting the liver scarring and 
therefore may be used to determine cirrhosis is present at initial assessment and 
its progression in the follow-up. Fibroscan results range from 2.5 kPa to 75 
kPa. Normal people without liver disease can have liver scarring measurement 
of < 6 kPa.  
ADVANTAGES: 
1. Rapid procedure 
2. Painless 
3. Results are immediately available 
4. No inter and intra observer variability 
5. Easy to perform in out patient clinic 
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FIBROSCAN MONITOR 
Liver stiffness assessment in identifying advanced fibrosis and cirrhosis 
using fibroscan outscores all noninvasive methods. 
LS <6kPa                  - normal 
LS between 8-12.5 - cut-off values to detect F3 and F4 fibrosis 
LS >20 kPa                - highly correlates with development of portal     
pressure, Esophageal varices 
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ROLE OF SERUM FERRITIN: 
Serum ferritin is elevated in hepatic inflammation. Values are elevated 
in ~60% of patients with NASH, but do not usually indicate an increase in 
hepatic iron stores because serum tranferin saturation or stainable iron in liver 
biopsy is not increased. 
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METHODS AND MATERIALS 
 
SOURCE OF THE STUDY: 
Data consists of primary data collected directly from the cases admitted 
in medical ward in Coimbatore Medical College and Hospital with Diabetes 
Mellitus. 
DESIGN OF THE STUDY: 
It is a Prospective study. 
PERIOD OF STUDY: 
 One year; July 2017 to June 2018 
METHODOLOGY: 
 This is a prospective study of 60 cases of diabetes mellitus with fatty 
liver admitted in the medical ward of Coimbatore Medical College and 
Hospital. Diabetes was confirmed with Fasting and post prandial blood sugar 
and HbA1c are screened for fatty liver with Ultrasound. Detailed history 
regarding duration of diabetes, history of drug intake , any other past illnesses 
were taken.Those patients with fatty liver are taken in to study and screened for 
fibrosis of liver using non invasive method – Fibroscan. Complete Blood count, 
Liver function test, Lipid profile, viral markers are done to all the patients. 
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INCLUSION CRITERIA: 
1. All patients above the age of 18 years diagnosed as diabetic (with WHO 
criteria). 
2. USG abdomen showing fatty liver. 
EXCLUSION CRITERIA: 
1. Patients with chronic liver disease of any other etiology other than 
NAFLD. 
2. Patients with history of hepatotoxic drug intake. 
3. History of alcohol consumption. 
4. Pregnancy. 
5. Dyslipidemia. 
6. Consent not given. 
USG GRADING OF FATTY LIVER: 
Grade 1 (mild) – Increased hepatic echogenicity with visible periportal and 
diaphragmatic echogenicity. 
Grade 2 (moderate) - Increased hepatic echogenicity with imperceptible 
periportal echogenicity, without obscuration of diaphragm. 
Grade 3 (severe) -  Increased hepatic echogenicity with imperceptible 
periportal echogenicity, with obscuration of diaphragm. 
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RESULTS 
 
TABLE 1: GRADING OF NAFLD BY ULTRASOUND 
USG  GRADING NO OF PATIENTS PERCENTAGE 
GRADE I 20 33% 
GRADE II 26 43% 
GRADE III 14 24% 
 
Total number of patients in this study is 60. Out of 60 patients 33% has Grade I 
fatty liver, 43% has Grade II fatty liver, 24% has grade III fatty liver. 
 
  
34%
43%
23%
USG GRADING OF NAFLD
GRADE I
GRADE II
GRADE III
 
 
39 
 
TABLE 2: AGE DISTRIBUTION 
AGE IN YEARS NO OF PATIENTS PERCENTAGE 
< 50 12 20% 
51-60 36 60% 
> 60 12 20% 
 
In this study majority are in the age group of 51 – 60 years. 
 
 
  
< 50, 12
51-60, 36
> 60, 12
AGE DISTRIBUTION
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TABLE 3: AGE DISTRIBUTION AMONG NAFLD 
USG  GRADING 
AGE IN YEARS 
MEAN SD 
GRADE I 54.2 5.97 
GRADE II 57.65 6.01 
GRADE III 56.71 4.21 
ANOVA 
P VALUE - 0.123 
NON  SIGNIFICANT 
 
 
  
52
53
54
55
56
57
58
GRADE I GRADE II GRADE III
54.2
57.65
56.71
MEAN AGE VS USG GRADE
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TABLE 4: SEX DISTRIBUTION 
SEX NO OF PATIENTS PERCENTAGE 
MALE 26 43% 
FEMALE 34 57% 
 
 
In this study majority are females. Out of 60 patients 34 (57%) are females  . 
 
  
43%
57%
SEX DISTRIBUTION
MALE
FEMALE
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TABLE 5: DISTRIBUTION OF SEX AMONG NAFLD 
USG  GRADING 
SEX 
MALE FEMALE 
GRADE I 8 12 
GRADE II 12 14 
GRADE III 6 8 
KRUSKAL WALLIS TEST 
P VALUE - 0.916 
NON  SIGNIFICANT 
 
Females are majority in this study. Females are 12, 14, 8 in number who has 
grade I, grade II, grade III fatty liver respectively 
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1212
14
6
8
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TABLE 6: TREATMENT DETAILS OF THE PATIENTS 
TREATMENT NO OF PATIENTS PERCENTAGE 
INSULIN 14 23% 
OHA 40 67% 
OHA+INSULIN 6 10% 
 
 
Out of 60 patients, 14 patients who was in insulin 5, 6, 3 patient has grade I, 
grade II, grade III fatty liver. 40 patients was on oral hypoglycemic drugs of 
which 14, 18, 8 patients has grade I, grade II, grade III fatty liver. 6 patients 
was on combined insulin and oral drugs.  
 
 
INSULIN
23%
OHA
67%
OHA+INSULIN
10%
TREATMENT
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TABLE 7: COMPARISON OF TREATMENT OF PATIENT  
WITH NAFLD 
USG  GRADING 
TREATMENT 
INSULIN OHA OHA+INSULIN 
GRADE I 5 14 1 
GRADE II 6 18 2 
GRADE III 3 8 3 
KRUSKAL WALLIS TEST 
P VALUE - 0.598 
NON  SIGNIFICANT 
 
 
 
  
5
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1
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3
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TABLE 8: BODY MASS INDEX OF THE PATIENTS. 
 
BMI (Kg/m2) NO OF PATIENTS PERCENTAGE 
MORE THAN 25 28 47% 
LESS THAN 25 32 53% 
 
 
 
  
47%
53%
BODY MASS INDEX
MORE THAN 25
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TABLE 9: BMI DISTRIBUTION IN NAFLD 
USG  GRADING 
BMI (Kg/m2) 
>25 <25 
GRADE I 4 16 
GRADE II 12 14 
GRADE III 12 2 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 10 : SGOT LEVEL IN THE PATIENTS 
SGOT (U/L) NO OF PATIENTS PERCENTAGE 
>35 16 27% 
<35 44 73% 
 
 
 
  
>35
27%
<35
73%
SGOT
 
 
48 
 
TABLE 11 : COMPARISON OF SGOT WITH GRADES OF FATTY 
LIVER IN NAFLD 
USG  GRADING 
SGOT (U/L) 
>35 <35 
GRADE I 0 20 
GRADE II 5 21 
GRADE III 11 3 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 12 : SGOT LEVEL IN THE PATIENTS 
SGPT (U/L) NO OF PATIENTS PERCENTAGE 
>35 17 28% 
<35 43 72% 
 
 
 
  
28%
72%
SGPT
>35
<35
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TABLE 13 : COMPARISON OF SGOT WITH GRADES OF FATTY 
LIVER IN NAFLD 
USG  GRADING 
SGPT (U/L) 
>35 <35 
GRADE I 1 19 
GRADE II 5 21 
GRADE III 11 3 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
 
  
1
19
5
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3
> 3 5 < 3 5
SGPT VS USG GRADE
GRADE I GRADE II GRADE III
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TABLE 14 : ALP LEVEL IN THE PATIENTS 
ALP (U/L) NO OF PATIENTS PERCENTAGE 
>150 12 20% 
<150 48 80% 
 
 
 
  
20%
80%
ALKALINE PHOSPHATASE
>150
<150
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TABLE 15 : COMPARISON OF ALP WITH GRADING OF FATTY 
LIVER IN NAFLD 
USG  GRADING 
ALKALINE PHOSPHATASE (U/L) 
>150 <150 
GRADE I 0 20 
GRADE II 4 22 
GRADE III 8 6 
KRUSKAL WALLIS TEST 
P VALUE - 0.001 
SIGNIFICANT 
 
 
 
  
0
20
4
22
8
6
> 1 5 0 < 1 5 0
ALP VS USG GRADE
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TABLE 16 : SERUM BILIRUBIN LEVEL IN THE PATIENTS 
BILIRUBIN NO OF PATIENTS PERCENTAGE 
ABNORMAL 2 3% 
NORMAL 58 97% 
 
 
 
  
3%
97%
SERUM BILIRUBIN
ABNORMAL
NORMAL
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TABLE 17 :COMPARISON OF BILIRUBIN WITH GRADING OF 
FATTY LIVER IN NAFLD 
USG  GRADING 
BILIRUBIN (mg/dl) 
ABNORMAL NORMAL 
GRADE I 0 20 
GRADE II 0 26 
GRADE III 2 12 
KRUSKAL WALLIS TEST 
P VALUE - 0.033 
SIGNIFICANT 
 
 
  
0
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2
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TABLE 18 : SERUM PROTEIN LEVEL IN THE PATIENTS 
SERUM PROTEIN NO OF PATIENTS PERCENTAGE 
ABNORMAL 2 3% 
NORMAL 58 97% 
 
 
 
  
ABNORMAL
3%
NORMAL
97%
SERUM PROTEIN
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TABLE 19 : COMPARISON OF SERUM PROTEIN WITH GRADING 
OF FATTY LIVER IN NAFLD 
USG  GRADING 
SERUM PROTEIN 
ABNORMAL NORMAL 
GRADE I 0 20 
GRADE II 0 26 
GRADE III 2 12 
KRUSKAL WALLIS TEST 
P VALUE - 0.033 
SIGNIFICANT 
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TABLE 20 : PLATELET LEVEL IN THE PATIENTS 
PLATELET COUNT NO OF PATIENTS PERCENTAGE 
ABNORMAL 2 3% 
NORMAL 58 97% 
 
 
  
3%
97%
PLATELET COUNT
ABNORMAL
NORMAL
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TABLE 21 : COMPARISON OF PLATELET COUNT WITH GRADES 
OF FATTY LIVER IN NAFLD 
USG  GRADING 
PLATELET COUNT 
ABNORMAL NORMAL 
GRADE I 0 20 
GRADE II 0 26 
GRADE III 2 12 
KRUSKAL WALLIS TEST 
P VALUE - 0.033 
SIGNIFICANT 
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TABLE 22 : COMPARISON OF FASTING BLOOD SUGAR WITH 
GRADES OF FATTY LIVER IN NAFLD 
USG  GRADING 
FASTING BLOOD SUGAR (mg%) 
MEAN SD 
GRADE I 127.7 8.87 
GRADE II 137.12 16.01 
GRADE III 158.01 21.8 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
 
 
  
12
7.
7 13
7.
12
15
8.
01
G R A D E  I G R A D E  I I G R A D E  I I I
MEAN FBS
 
 
60 
 
TABLE 23 : COMPARISON OF POST PRANDIAL BLOOD SUGAR 
WITH GRADES OF FATTY LIVER IN NAFLD 
USG  GRADING 
POST PRANDIAL BLOOD SUGAR (mg%) 
MEAN SD 
GRADE I 151.05 12.02 
GRADE II 168.5 26.18 
GRADE III 198.86 52.08 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 24 : COMPARISON OF HBA1C WITH GRADES OF 
 FATTY LIVER IN NAFLD 
USG  GRADING 
HBA1C (%) 
MEAN SD 
GRADE I 6.08 0.68 
GRADE II 6.73 0.78 
GRADE III 8.36 0.92 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
 
70 
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TABLE 25 : COMPARISON OF DURATION OF DISEASE WITH 
GRADES OF FATTY LIVER IN NAFLD 
USG  GRADING 
DISEASE DURATION IN YEARS 
MEAN SD 
GRADE I 5.75 1.07 
GRADE II 6.54 1.63 
GRADE III 6.64 2.02 
ANOVA 
P VALUE - 0.167 
NON  SIGNIFICANT 
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TABLE 26 : COMPARISON OF Kpa LEVEL OF FIBROSCAN WITH 
FATTY LIVER IN NAFLD 
USG  GRADING 
Kpa 
MEAN SD 
GRADE I 5.42 1.17 
GRADE II 7.11 1.89 
GRADE III 12.22 1.34 
ANOVA 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 27 :COMPARISON OF Kpa LEVEL OF FIBROSCAN WITH 
AGE OF PATIENTS 
Kpa 
AGE IN YEARS 
MEAN SD 
<6 54.04 5.89 
>6 58 5.07 
UNPAIRED T TEST 
P VALUE - 0.007 
SIGNIFICANT 
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.0
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KPA VS AGE
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TABLE 28 : COMPARISON OF Kpa LEVEL OF FIBROSCAN WITH 
FBS OF PATIENTS 
kPa 
FASTING BLOOD SUGAR (mg%) 
MEAN SD 
<6 128.69 9.31 
>6 146.62 21.23 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 29 : COMPARISON OF Kpa LEVEL OF FIBROSCAN WITH 
PPBS OF PATIENTS 
kPa 
POSTPRANDIAL BLOOD SUGAR (mg%) 
MEAN SD 
<6 153.15 13.11 
>6 182.47 41.59 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 30 : COMPARISON OF Kpa LEVEL OF FIBROSCAN WITH 
HBA1C OF PATIENTS 
kPa 
HBA1C (%) 
MEAN SD 
<6 6.11 0.64 
>6 7.49 1.12 
UNPAIRED T TEST 
P VALUE - 0.001 
SIGNIFICANT 
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TABLE 31 : COMPARISON OF Kpa LEVEL OF FIBROSCAN WITH 
DURATION OF DIABETES 
Kpa 
DURATION OF DISEASE IN YEARS 
MEAN SD 
<6 5.65 0.97 
>6 6.79 1.8 
UNPAIRED T TEST 
P VALUE - 0.005 
SIGNIFICANT 
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TABLE 32 : COMPARISON OF Kpa LEVEL OF FIBROSCAN WITH 
SGPT OF PATIENTS 
Kpa 
SGPT (U/L) 
>35 <35 
<6 1 25 
>6 17 18 
CHI SQUARE TEST 
P VALUE - 0.001 
SIGNIFICANT 
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DISCUSSION 
 
DISTRIBUTION OF SEVERITY OF FATTY LIVER ON USG: 
In this study, 33% of patients had grade I, 43% had grade II and 24% 
had grade III fatty liver. A study conducted by Roli Agarval et al showed that 
48.1%, 40.3%, 11.3% had grade I, II, III fatty liver respectively which was 
comparable to the observations made in this study. 
COMPARING MEAN AGE GROUP WITH USG: 
Of 60 patients, 12 patients are of age group <50 years, 36 patients  are 
between 51-60 years and 12 patients belongs to age group >60 years. 
Mean age of patients who had grade I, grade II, grade III fatty liver was 
54.2 years, 57.65 years, 56.71 years respectively. No statistically significant 
relationship was found between age and ultrasound grading of fatty liver. 
USG GRADING AND SEX: 
 In this study, 43% are male and 57% are female. Females are majority in 
this study. In an Indian study by D Amarapurkar et al in which there was 
female predominance of 52.2%. In this study female patients are high in 
number in grade I, II, III fatty liver. But it is not statistically significant. 
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USG GRADING AND BMI: 
 BMI was > 25 kg/m2 in 28 patients other patients had BMI < 25kg/m2. 
In the study done by Daad H Akbhar et al, obesity was identified as an 
independent factor for development of NAFLD. (57) 
 Out of 28 patients with BMI > 25 kg/m2 , 4 patients had grade I , 12 had 
grade II and 12 had grade III fatty liver which are statistically significant. 
LIVER FUNCTION TEST: 
 In this study, 27% (16 patients)  had SGOT >35 U/L . Of these 16 
patients, 5 patients had grade II and 11 patients had grade III fatty liver. 
 28% (17 patients) had SGPT >35 U/L and 1 patient, 5 patients, 11 
patients had fatty liver of grade I, II, III respectively. 
 20% (12 patients) had ALP >150 U/L , of these 4 had grade II and 12 
had grade III fatty liver. 
 All three are statistically significant. 
 Only 2 patients had abnormal serum bilirubin and serum protein level. 
Other 58 patients had normal values. 
 Roli Agarwal et al reports elevated SGOT and SGPT in 97.6% and 
98.4%  respectively. Mofrad et al (58) studied NAFLD in 2 groups. Of which 
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one group comprises of 50 cases showed normal SGPT values and second 
group comprises of 50 cases with elevated SGPT values. 
COMPARING FBS, PPBS, HbA1c WITH USG: 
 Patients with grade I fatty liver had mean FBS of 127.7 mg%, grade II 
had mean FBS of 137.12 mg% and grade III had mean FBS of 158.01 mg%.  
 Mean PPBS was 151.08 mg%, 168.5 mg%, 198.86 mg% in grade I, II, 
III fatty liver. 
 Mean HbA1c was 6.08% , 6.73%, 8.36%  in grade I , II and III fatty 
liver group respectively. 
 All 3 i.e.,FBS, PPBS, HbA1c with USG are statistically significant. 
COMPARING Kpa OF FIBROSCAN WITH USG: 
 In this study the mean Kpa value for the patients with grade I fatty liver 
was 5.42, grade II was 7.11, grade III was 12.22. 
COMPARING Kpa OF FIBROSCAN WITH FBS, PPBS, HbA1c: 
 In this study patient with Kpa <6 had  mean FBS, PPBS, HbA1c of 
128.69 mg%, 153.15 mg%, 6.11 % respectively. 
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COMPARING Kpa VALUE OF FIBROSCAN WITH SGPT: 
 Of 60 patients, 17 patients who had SGPT >35 U/L had Kpa value >6 
which is statistically significant. 
LIVER STIFFNESS ASSEESSMENT: 
 Of 60 patients, 32 patients has Kpa value <6, 14 patients has Kpa value 
between 6 – 8 , 18 patients has Kpa between 8 – 12.5 Kpa (F3 fibrosis), 6 
patients has Kpa values >12.5 (F4 fibrosis). 
 The patients who has grade I, Grade II, Grade III fatty liver has mean 
Kpa values of 5.42, 7.11, 12.22 . 
LIMITATION: 
1. Small study group since fibroscan cannot be done in more number of 
patients. 
2. Selection bias towards the patients. 
3. Lack of histological confirmation since liver biopsy remains gold 
standard. 
4. Blood test like AST may fluctuate and may increase in non liver 
related problems like muscle injury.  
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CONCLUSION 
1. Patients with diabetes has higher prevalence of NAFLD than patient 
with non diabetes. 
2. In this study, females sex group has  higher prevalence of occurance of 
Non alcoholic fatty liver disease. (57%) and the common age group was 
51 – 60 years. 
3. There was significant relation observed between Body mass index, 
Fasting blood sugar, Post prandial blood sugar, HbA1c, SGPT, SGOT 
and the prevalence of fatty liver by USG. Diabetic control correlates 
well with the study. Uncontrolled diabetic have high grade of fibrosis. 
4. 3 patients with grade 2 fatty liver has Kpa value of more than >12. 
Hence fibroscan helps in early diagnosis of fibrosis. 
5. There was no significant relation observed between age, duration of 
disease with NAFLD. 
6. Out of 60 patients only 2 patients has abnormal serum bilirubin, serum 
protein and platelet values. 
  
 
 
75 
 
BIBLIOGRAPHY 
1. Schaffner F, Thaler H, Non alcoholic fatty liver disease . Prog liver 
disease1986;8:283-98. 
2. Prevalence of Fatty Liver Disease among Type 2 DiabetesMellitus 
Patients and its Relation to Insulin Resistance,S Merat et al, Middle East 
Journal of Digestive Diseases/ Vol.1/ No.2/ September 2009. 
3. Ludwig Y, Viggiano TR, McGill DB, ctt BJ, Nonalcoholic 
steatohepatitis: Mayo Clin Proc 1980, 55:434-438.  
4. Marchesini G, Brizi M, Morselle labate AM, et al NAFLD and insulin 
resistance: Am J Med 1999: 107:450-5. 
5. Guidorizzi de siqueira AC, Cotrim, Rocha, et al NAFLD and insulin 
resistance. Eur J gastroenterol hepatol 2005:17:837-41. 
6. Chitturi S, Abeygunasekara S, Farrell GC, et al. NASH and insulin 
resistance. Hepatology 2002, 35:373-9. 
7. Silverman JF, Pories WJ, Caro JF. Liver pathology in diabetes mellitus 
and morbid obesity. Pathol Annu 1989, 24:275-302. 
8. Zelman.S. The liver in obesity. Arch. Internal Medicine 1952; 90:141-
156 Overview: an introduction to NASH and related fatty liver 
disordersGeoffrey C. Farrell, et al, book- First published 2005. 
 
 
76 
 
9. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. 
Prevalence of fatty liver in a general population of Okinawa, Japan.  Jpn 
J Med 1988;27:142-9. 
10. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk 
factors for hepatic steatosis in northern Italy. Ann Intern Med 
2000;132:112-7. 
11. Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely 
obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes 
Relat Metab Disord 1998;22:222-6. 
12. Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the 
Asia-Pacific region: future shock? J Gastroenterol Hepatol 2004; 19 : 
368-74. 
13. Mohan V, Farooq S, Deepa M et al. Prevalence of non-alcoholic fatty 
liver disease in urban south Indians in relation todifferent grades of 
glucose intolerance and metabolic syndrome. Diabetes Res ClinPract. 
2009;84:84-91 
14. Struben VM, Hespenheide EE, Caldwell SH. NASH and cryptogenic 
cirrhosis within kindreds. Am.J. Med 2000;108: 9-13 
 
 
77 
 
15. Willner IR, Waters B, Patil SR et al. Ninety patients with NASH: insulin 
resistance, familial tendency, and severity of disease. 
Am.J.gastroenterol.2001;96:2957-61 
16. Adelmalek MF, Liu C, Shuster J et al. familial aggregation of insulin 
resistance in first degree relatives of patient with NAFLD.Clin. 
gastroenterol.hepatol.2006;4:1162-69. 
17. Peterson KF, Dufour S, Befroy et al. Impaired mitochondrial activity in 
the insulin-resistant offspring of diabetes with type 2 diabetes with type 
2 diabetes.N.Engl.J.Med 2004;350;664-671. 
18. GI Epidemiology: nonalcoholic fatty liver disease,P. ANGULO, 
Aliment PharmacolTher 25, 883–889. 
19. Day CP. Pathogenesis of steatohepatitis. Balliere’s Best Pract Res 
ClinGastroenterol2002; 16: 663–78 
20. Lemasters JJ Dying a thousand deaths: Redundant pathways from 
different organelles to apoptosis and necrosis.Gatroenterology 
2005;129:351-360 
21. Amidi F, French BA , Chung D et al.M-30 and 4HNE are sequestered in 
different aggresomes.Exp .Mol.path 2007;83:296-300 
 
 
78 
 
22. Su Q,Tsai J,XU E et al. Apolipoprotein B100 acts as a molecular link 
between lipid induced endoplasmic reticulum stress and hepatic insulin 
resistance. Hepatology 2009;50:77-84 
23. Friedman SL. Hepatic stellate cells: Protean, multifunctional, and 
enigmatic cells of the liver.Physiol.rev.2008;88:125-172 
24. Simple Noninvasive Systems Predict Long-term Outcomes of Patients 
With Nonalcoholic Fatty Liver Disease,Paul Angulo, Elisabetta 
Bugianesi, Einar S. Bjornsson, Phunchai. 
25. GI Epidemiology: nonalcoholic fatty liver disease,P. ANGULO, 
Aliment PharmacolTher 25, 883–889. 
26. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver 
disease: a spectrum of clinical and pathological severity. 
Gastroenterology 1999; 116:1413–9. 
27. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical  
features and natural history of NASH syndromes. Semin Liver Dis 
2001; 21:17-26. 
28. Paggioni R, Fantuzzi G, Gabay C et al, Leptin deficiency enhances  
sensitivity to endotoxin-induced lethality. Am J Physiol 1999;276:R136 
R142. 
 
 
79 
 
29. Rashid M, Roberts EA. NASH in children. J Pediatr Gastroenterol Nutr 
2000;30:48-53. 
30. Leonarduzzi G, Scavazza, A, Biasi F, et al. The Lipid peroxidation end  
product $-hydroxy-2,3-noneal up-regulates TGF β1 expression in the  
macrophage lineage: a link between oxidative injury and fibrosclerosis. 
FASEB J 1997;11:851-857.  
31. Curzio M, Esterbauer H, Dianzani MU. Chemotactic activity of  
hydroxyalkenals on rat neutrophils. Int J Tissue React 1985;7:147-142. 
32. Manton ND, Lipsett J, Moore DJ, Davidson GP< Bourne AJ, Couper  
RTI, NASH in children and adolescents. Med J Aust 2000;173:476-479.  
33. Caldweel SH, Oelsner DH, lezzoni JC, Hespenheide EE, Battle 
EH,Driscoll CJ. Crptogenic cirrhosis: clinical characterization and risk 
factors for underlying disease. Hepatology 1999;29:664-669. 
34. Angul P, Keach JC, Batts KP, Lindor KD. Independent predictors of  
liver fibrosis in patients with NASH. Hepatology 1999;30:1356-1362.  
35. Bacon BR< Farahvash MJ, Janney CG, Neuschwander-Tetri BA>  
NASH: an expanded clinical entity. Gastroenterology.1994;107:1103 
1109. 
 
 
80 
 
36. Pantsari MW, Harrison SA. Nonalcoholic fatty liver disease presenting 
with an isolated elevated alkaline phosphatase. J ClinGastroenterol. 
2006;40:633–635. 
37. Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. 
Severe liver fibrosis or cirrhosis:accuracy of UG for detection-analysis 
300 cases.Radiology  2003;227:89-94 
38. Abate N, Burns D, Peshock RM, Garg A, Grandy SM. Estimation of 
adipose tissue mass by MRI: validation against dissection in human 
cadavers. Lipid Res 1994;35:1490-6 
39. Leen E, Goldberg JA, Angerson WJ, McArdle CS. Potential role of 
Doppler perfusion index in selection of patients with colorectal cancer 
for adjuvant chemotherapy. Lancet. 2000; 355:34–37. 
40. Jacobs JE, Birnbaun BA, Shapiro MA, et al. Diagnostic criteria for fatty 
infiltration of the liver on contrast-enhanced helical CT. AJR Am J 
Reontgenol 1998;171;659-64 
41. 41.Alpren MB, Lawson TL, Foley DW, et al. Focal hepatic masses and 
fatty infiltration detected by enhanced dynamic CT. Radiology 
1986;158:45-9 
 
 
81 
 
42. 42.Schlemmer H-P, Sawatzki T, Sammet S et al. Hepatic phospholipids 
in alcoholic liver disease assessed by proton decoupled 31P MR 
spectroscopy. J Hepatol 2005;42:752-9. 
43. 43.Hall P de la M, Kirsch R (2005) patology of steatosis, NASH and 
related condition.In:Farrell GC, George J, Hall Pde la M et al. Fatty liver 
disease.NASH and related disorders.Malden ,MA Blackwell publishing , 
pp13-22. 
44. 44.  Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri 
BA,Bacon BR. Non alcoholic steatohepatitis: a proposal for grading  
and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–
2474. 
45. 45. Liver stiffness: a novel parameter for the diagnosis of liver disease, 
Hepatic Medicine: Evidence and Research may 2010: 249–67. 
 
 
 
 
 
 
 
 
 
82 
 
NON INVASIVE ASSESSMENT OF FIBROSIS OF LIVER 
USING FIBROSCAN IN PATIENTS WITH DIABETES 
MELLITUS 
THESIS  PROFORMA 
GUIDE:        CANDIDATE: 
GENERAL INFORMATION 
Name :      
Age/sex : 
Hospital No : 
Address :   Phone: 
Occupation : 
Literacy : 
Per capita income: 
Religion : Hindu/Muslim/Christian/Others 
Diet :Veg/Non Veg/Mixed 
Present history 
S.No SYMPTOM PRESENT ABSENT DURATION 
1. Abdominal pain    
2. Abdominal distension    
3. Dyspepsia    
4. Jaundice    
5. UGI bleed    
6. Oedema legs    
7. Complications of diabetes    
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HISTORY DURATION DRUGS 
DIABETES MELLITUS   
CAD   
HYPERTENSION   
DYSLIPIDEMIA   
CHRONIC LIVER DISEASE   
THYROID DISORDERS   
CHRONIC KIDNEY DISEASE   
MALIGNANCY   
 
Any other Drugs: 
Parentral nutrition:     YES/NO 
H/O: 
Jaundice                     : 
Abdominal Surgery   : 
Blood Transfusion    : 
Starvation                 : 
HBV                         : 
HCV                         : 
Family H/O: 
Personal H/O : 
 Alcohol  : 
 Smoking: 
          Any other substance Abuse: 
 IV Drug abuse: 
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GENERAL EXAMINATION: 
 B.P:                  P.R                Ht:               WT:                  BMI :       
           Anemia-         Icterus-          Clubbing-      Cyanosis-        Pedal edema-      
    CVS- 
                R.S- 
Per Abdomen – 
              CNS- 
INVESTIGATIONS: 
Tc  
Hb  
Platelet  
Urea  
Creatinine  
FBS  
PPBS  
HBA1C  
LFT: 
        1.S.Bilirubin/direct bilirubin 
        2.SGOT/SGPT/ALP 
        3.Protein/Albumin 
 
HBsAg  
Anti HCV  
HIV  
PT/INR  
CHOL/TGL/LDL/HDL  
USG Abdomen  
Fibroscan  
DIAGNOSIS: 
 
INVESTIGATOR: 
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MASTER CHART 
S.No NAME AGE/SEX FBS PPBS HbA1c YEARS Kpa TREATMENT BMI SGOT SGPT ALP CHOLESTEROL TGL HDL USG BILIRUBIN S.PROTEIN PLATELETS 
1 gopinath 70/m 144 176 7 7 5.8 insulin <25 <35 <35 <150 <200 <150 HIGH(>40) GR 1 NORMAL NORMAL NORMAL 
2 jacob 50/m 123 147 6 5 4.6 OHA >25 <35 <35 <150 >200 >150 HIGH GR 1 NORMAL NORMAL NORMAL 
3 pushpavalli 45/f 127 148 5.4 5 4.9 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
4 nallendren 62/m 131 161 6.2 8 6.1 insulin+OHA <25 <35 <35 <150 <200 <150 LOW(<40) GR 1 NORMAL NORMAL NORMAL 
5 bhuvaneshwari 54/f 120 142 5.1 5 4.7 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
6 rajeshwari 61/f 150 190 7 8 7.7 OHA <25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
7 sandhiya 53/f 138 164 6.7 5 6.8 insulin <25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
8 maniyan 71/m 154 188 7.6 10 9 OHA >25 >35 >35 <150 >200 >150 LOW GR 2 NORMAL NORMAL NORMAL 
9 prabavathy 62/f 141 177 6.6 7 6.1 OHA <25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
10 padmavathy 66/f 123 146 5.6 5 4.4 OHA >25 <35 <35 <150 >200 >150 HIGH GR 1 NORMAL NORMAL NORMAL 
11 chitra 55/f 133 171 6.2 5 6.1 OHA >25 <35 <35 <150 <200 <150 LOW GR 2 NORMAL NORMAL NORMAL 
12 anandavel 60/f 141 169 5.9 6 5.8 OHA <25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
13 rukmani 52/f 118 139 5 4 4.8 OHA >25 <35 <35 <150 >200 >150 HIGH GR 1 NORMAL NORMAL NORMAL 
14 radhamani 60/f 161 121 8.5 6 14 OHA >25 >35 >35 >150 <200 <150 LOW GR 3 NORMAL NORMAL NORMAL 
15 shanthi 49/f 118 156 5.8 5 5.8 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
16 deivanai 54/f 161 191 9 5 13.8 OHA >25 <35 <35 >150 >200 >150 LOW GR 3 2.1 <3.5 1.12 L 
17 murugesan 54/m 138 155 6.8 6 8.1 insulin <25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
18 vanitha 48/f 118 138 4.8 5 4.6 OHA <25 <35 <35 <150 <200 <150 LOW GR 1 NORMAL NORMAL NORMAL 
19 rajendren 49/m 131 147 6.1 5 6.1 OHA >25 <35 <35 <150 >200 >150 HIGH GR 2 NORMAL NORMAL NORMAL 
20 sundari 50/f 122 155 5.8 5 5.9 OHA >25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
21 lakshmi 56/f 153 192 8.6 6 11.1 insulin <25 <35 <35 <150 <200 <150 LOW GR 3 NORMAL NORMAL NORMAL 
22 siva kumar 58/m 130 145 5.8 6 5.9 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
23 krishnan 45/m 118 141 6 5 5.2 OHA >25 <35 <35 <150 >200 >150 HIGH GR 2 NORMAL NORMAL NORMAL 
24 kumar 56/m 125 150 6.2 6 5.5 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
25 indira 66/f 124 144 6.4 8 8.5 insulin >25 >35 >35 <150 >200 >150 HIGH GR 2 NORMAL NORMAL NORMAL 
26 logeshwari 30/f 125 151 6.5 16 7.5 insulin >25 <35 <35 <150 <200 <150 LOW GR 2 NORMAL NORMAL NORMAL 
27 geetha 64/f 186 232 9 10 12 insulin+OHA >25 >35 >35 >150 >200 >150 LOW GR 3 NORMAL NORMAL NORMAL 
28 mohan 60/m 111 138 6 5 6.1 OHA <25 <35 <35 <150 <200 <150 LOW GR 2 NORMAL NORMAL NORMAL 
29 palanivel 62/m 148 188 6.5 7 5.2 insulin >25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
30 sadhasivam 65/m 108 130 5.6 5 8.8 OHA >25 >35 >35 >150 >200 >150 LOW GR 2 NORMAL NORMAL NORMAL 
31 amsaveni 51/f 118 139 6.1 5 4.6 insulin <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
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32 kalidas 58/m 181 289 9.8 7 11.2 insulin+OHA >25 >35 >35 >150 >200 >150 LOW GR 3 NORMAL NORMAL NORMAL 
33 kuppusamy 54/m 141 163 7 6 5.7 OHA >25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
34 ananth 56/m 134 159 7 6 5.7 OHA <25 <35 <35 <150 >200 >150 LOW GR 2 NORMAL NORMAL NORMAL 
35 ponnusamy 62/m 141 187 7.3 8 6.9 insulin+OHA <25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
36 malliga 57/f 188 259 9 9 10 OHA <25 >35 >35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
37 banumathi 60/f 149 201 8.8 10 12.6 OHA >25 >35 >35 <150 >200 >150 LOW GR 3 NORMAL NORMAL NORMAL 
38 chinnan 54/m 128 152 5.6 5 5.6 OHA <25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
39 kannan 49/m 118 140 5.6 5 4.3 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
40 sakthivel 56/m 143 177 7.5 8 14 OHA >25 >35 >35 >150 >200 >150 LOW GR 3 NORMAL NORMAL NORMAL 
41 malarkodi 56/f 131 163 6.1 6 5.6 insulin <25 <35 <35 >150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
42 rajan 64/m 136 170 8.5 10 10.2 insulin >25 >35 >35 <150 <200 <150 HIGH GR 3 NORMAL NORMAL NORMAL 
43 nallammal 53/f 151 189 7.8 5 8.8 OHA <25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
44 savithri 59/f 144 180 7 10 9.5 insulin+OHA <25 <35 <35 <150 >200 >150 LOW GR 2 NORMAL NORMAL NORMAL 
45 sankar 48/m 132 156 6.7 5 6.5 OHA >25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
46 anuradha 50/f 144 171 7.1 5 4.9 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
47 natchammal 52/f 134 158 7 5 12 OHA >25 >35 >35 >150 >200 >150 LOW GR 3 NORMAL NORMAL NORMAL 
48 perumal 60/m 138 161 6.7 7 8 insulin <25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
49 subramani 58/m 133 151 6.5 6 6.6 insulin <25 <35 <35 <150 <200 <150 LOW GR 2 NORMAL NORMAL NORMAL 
50 senthil 57/m 144 171 7.5 5 11.4 insulin >25 >35 >35 <150 >200 >150 LOW GR 3 NORMAL NORMAL NORMAL 
51 latha 31/f 140 162 6.5 15 5.1 insulin <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
52 nirmala 55/f 128 149 6.4 5 5.4 OHA <25 <35 <35 <150 <200 <150 HIGH GR 2 NORMAL NORMAL NORMAL 
53 saraswathy 57/f 150 191 7.3 7 6.1 OHA >25 <35 <35 <150 >200 >150 HIGH GR 2 NORMAL NORMAL NORMAL 
54 srinivasan 50/m 142 171 7.1 5 10.5 OHA >25 <35 <35 <150 >200 >150 LOW GR 3 NORMAL NORMAL NORMAL 
55 ramesh 55/m 149 181 7.8 5 13 OHA >25 >35 >35 >150 >200 >150 LOW GR 3 NORMAL NORMAL NORMAL 
56 meenatchi 48/f 128 146 6 5 4.8 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
57 pushpavalli 55/f 131 151 6.1 6 4.9 insulin <25 <35 >35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
58 arumugam 65/m 139 161 6.6 8 5.5 OHA <25 <35 <35 <150 >200 >150 LOW GR 2 NORMAL NORMAL NORMAL 
59 chellammal 59/f 151 190 8 7 13.2 OHA >25 >35 >35 >150 >200 >150 HIGH GR 2 NORMAL NORMAL NORMAL 
60 mary 50/f 120 139 6 5 4.9 OHA <25 <35 <35 <150 <200 <150 LOW GR 1 NORMAL NORMAL NORMAL 
61 mohammed 60/m 130 151 6.8 8 5.8 insulin >25 <35 <35 <150 <200 <150 LOW GR 1 NORMAL NORMAL NORMAL 
62 duraisamy 58/m 140 174 7 6 5.2 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
63 malliga 55/f 128 146 6.2 6 5.4 OHA <25 <35 <35 <150 >200 >150 HIGH GR 1 NORMAL NORMAL NORMAL 
64 paapathy 60/f 125 146 6.4 7 9.9 insulin >25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
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65 vishwanathan 60/m 162 212 9 8 10.2 OHA >25 <35 <35 <150 >200 >150 HIGH GR 2 NORMAL NORMAL NORMAL 
66 selvi 56/f 212 321 10 5 11.4 insulin+OHA <25 >35 >35 <150 >200 >150 LOW GR 3 NORMAL NORMAL NORMAL 
67 ravi 55/m 125 148 6.2 5 5.1 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
68 suresh 50/m 131 154 6.6 5 5.3 OHA <25 <35 <35 <150 <200 <150 HIGH GR 1 NORMAL NORMAL NORMAL 
69 suganthi  52/f 161 209 8 6 14 OHA >25 >35 >35 >150 >200 >150 LOW GR 3 2.2 <3.5 1.23 L 
70 vimala 59/f 132 151 7 7 6.6 insulin >25 <35 <35 >150 <200 <150 LOW GR 2 NORMAL NORMAL NORMAL 
 
 
